Combination therapy targets aggressive lymphoma in CLL patients
NCT ID NCT03054896
First seen Jul 10, 2026 · Last updated Jul 10, 2026
Summary
This study tests whether adding the targeted drug venetoclax to standard chemotherapy (R-EPOCH or R-CHOP) can improve outcomes for people with Richter's syndrome, an aggressive lymphoma that can develop from chronic lymphocytic leukemia (CLL). The trial enrolls adults with biopsy-confirmed Richter's syndrome. The main goal is to see how many patients achieve complete remission after three months of treatment.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- Venetoclax (Venclexta) plus chemotherapy (R-EPOCH or R-CHOP)
- What this could lead to
- If successful, this combination could offer a more effective treatment option for Richter's syndrome, potentially improving remission rates and survival.
- What could go wrong
- This is a Phase 2 trial with a relatively small number of participants. The combination may cause significant side effects, and it is not yet known if it will be better than standard therapy alone.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for RICHTER SYNDROME are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Dana Farber Cancer Institute
Boston, Massachusetts, 02215, United States
-
MD Anderson Cancer Center
Houston, Texas, 77030, United States
-
Ohio State University
Columbus, Ohio, 43210, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Immunotherapy combo shows promise for Tough-to-Treat blood cancers
- New combo therapy aims to keep lymphoma at bay after transplant
- New drug duo shows promise for Tough-to-Treat blood cancers
- Triple-Drug attack aims to wipe out Hard-to-Treat leukemia
- New drug combo targets aggressive lymphoma in CLL patients
- New drug cocktail shows promise for Tough-to-Treat lymphomas